Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
EVE Health Group Limited ( (AU:EVE) ) just unveiled an update.
EVE Health Group has completed a share consolidation on a forty-to-one basis, as approved by shareholders. This move results in a new capital structure with 131,862,715 ordinary shares. The consolidation aims to streamline the company’s capital structure, potentially enhancing its market position and operational efficiency. Trading on a normal T+2 settlement basis will resume on 12 June 2025.
More about EVE Health Group Limited
EVE Health Group (ASX: EVE) is an Australian-based health company focused on developing and commercializing evidence-based wellness and pharmaceutical products. Through its subsidiaries, Meluka Australia and the soon-to-be-acquired Nextract, EVE provides science-led innovations for consumer and practitioner health across retail, pharmacy, and clinical channels.
Average Trading Volume: 1,278,384
Technical Sentiment Signal: Sell
Current Market Cap: A$4.75M
Learn more about EVE stock on TipRanks’ Stock Analysis page.